GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (OTCPK:AIMI) » Definitions » Degree of Operating Leverage

AIMI (AIM ImmunoTech) Degree of Operating Leverage : 2.18 (As of Mar. 2025)


View and export this data going back to 1995. Start your Free Trial

What is AIM ImmunoTech Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. AIM ImmunoTech's Degree of Operating Leverage for the quarter that ended in Mar. 2025 was 2.18. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for AIM ImmunoTech's Degree of Operating Leverage or its related term are showing as below:

AIMI's Degree of Operating Leverage is ranked worse than
77.95% of 880 companies
in the Biotechnology industry
Industry Median: -0.02 vs AIMI: 2.18

AIM ImmunoTech Degree of Operating Leverage Historical Data

The historical data trend for AIM ImmunoTech's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Degree of Operating Leverage Chart

AIM ImmunoTech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.22 -2.17 1.22 1.00 2.66

AIM ImmunoTech Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.14 1.76 -4.50 2.66 2.18

Competitive Comparison of AIM ImmunoTech's Degree of Operating Leverage

For the Biotechnology subindustry, AIM ImmunoTech's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AIM ImmunoTech's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's Degree of Operating Leverage falls into.


;
;

AIM ImmunoTech Degree of Operating Leverage Calculation

AIM ImmunoTech's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -14.571 (Mar. 2025) / -31.046 (Mar. 2024) - 1 )/( 0.146 (Mar. 2025) / 0.193 (Mar. 2024) - 1 )
=-0.5307/-0.2435
=2.18***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


AIM ImmunoTech  (OTCPK:AIMI) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


AIM ImmunoTech Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


AIM ImmunoTech Business Description

Traded in Other Exchanges
Address
2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
Executives
Rodino Peter W. Iii director 2117 SOUTHWEST HIGHWAY 484, OCALA FL 34473
Thomas K. Equels director, officer: Vice Chairman of Board 2117 SOUTHWEST HIGHWAY 484, OCALA FL 34473
William M Mitchell director 2117 SW HWY 484, OCALA FL 34473
Stewart Appelrouth director 2117 SW HIGHWAY 484, OCALA FL 34473
Nancy Bryan director 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Ellen M Lintal officer: CFO 2117 SW HWY 484, OCALA FL 34473
David R Strayer other: Medical Director 600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
Wayne S. Springate officer: VP of Operations 600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
Adam Pascale officer: CFO 600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
Ralph Christopher Cavalli officer: VP, Quality Control 510 MURDOCH ROAD, PHILADELPHIA PA 19119
Russel J Lander officer: VP of Process/QualityAssurance 784 BAEDER ROAD, JENKINTOWN PA 19046
Robert Iv Dickey officer: Senior Vice President 320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Bernhardt Charles Thomas Iii officer: CFO 23 BIRCH ROAD, MALVERN PA 19355
Steven D Spence director 250 EAST 54TH STREET APARTMENT 36C, NEW YORK NY 10022
Anthony Bonelli officer: President & COO P.O. BOX 521, NEW VERNON NJ 07976